| Name | Title | Contact Details |
|---|
Were in the business of building businesses—whether youre an individual, a community, or an organization, weve got you covered. We take face to face events to the next level by sprinkling in some serious data smarts and digital wizardry. Think market insights, product sourcing, and deal-closing magic, all in one place. With over 400 events across 22 countries, we create experiences that are as engaging as they are impactful. And with digital tools in the mix, were all about supporting growth—whether youre showing up in person or rocking it virtually. But were not stopping there. Were turning our flagship events into year-round communities across 42 industries (yes, 42!). From aerospace to pop culture, beauty to building, and everything in between, weve got something for everyone. So whether youre into jewellery, IT, sports, or snacks (hello, food service), were here to make big things happen. Were also big on making a difference. Positive impact? Check. Inclusive work environment? Double check. At RX, we believe everyone deserves to thrive, no matter who you are or where youre from. Oh, and in case youre wondering, were part of RELX, a global powerhouse in information-based analytics. With a presence in 180 countries and over 33,000 employees (half in North America), were not just playing the game—were changing it. RX Privacy Policy https://privacy.rxglobal.com/
Chicago Central District is a Bourbonnais, IL-based company in the Business Services sector.
Thompson-Brooks is a San Francisco, CA-based company in the Business Services sector.
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
Umanageit & Associates is a Riverside, CA-based company in the Business Services sector.